H3 Dynamics Announces Hydrogen Production, Storage and Filling Stations for Long-Range Hydrogen Drones & UAVs
4.1.2023 10:30:00 CET | Business Wire | Press Release
H3 Dynamics is announcing the global launch of H2FIELD-1, a new hydrogen station capable of producing hydrogen in the field for unmanned aerial vehicles of all shapes, sizes and configurations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005066/en/
H3 Dynamics announces H2FIELD mobile hydrogen station for hydrogen drones and UAVs of all shapes and sizes, from hydrogen production to automatic refilling in the field. (Photo: Business Wire)
Now hydrogen-powered airships, multi-rotors, vertical take-off and landing UAS and various fixed wing systems will be able to benefit from 24/7 hydrogen supply anywhere, anytime.
H2FIELD’s rugged IP-65 trailer-based solution brings hydrogen production to different drone operation locations. It can also be dismounted as a permanent installation and connect to solar panel arrays. H3 Dynamics can supply various configurations, with slow or fast charge options down to minutes per fill - depending on client requirements. H3 Dynamics’ system is extremely compact and can produce hydrogen on site - not just dispense it from other storage forms.
For hydrogen drone operators, H2FIELD-1 solves fundamental hydrogen accessibility in remote areas, unlocking a major logistical barrier for a growing base of hydrogen drone operators in industrial, defense, or even academic sectors. The only feedstock input is water.
H3 Dynamics has been working on a first transatlantic hydrogen-electric flight using liquid hydrogen storage systems currently being tested in France with ISAE-SUPAERO in Toulouse. Last week H3 Dynamics announced its hydrogen propulsion partnership with French airship maker HyLight, and the week prior with Australian VTOL UAV producer Carbonix whose airframes are made by Quickstep - Australia’s leading aerospace composites producer.
2023 will see more of these announcements as H3 Dynamics continues to transition battery-UAS manufacturers to hydrogen technologies. Compared to batteries, hydrogen electric systems increase battery-drone flight durations by several orders of magnitude, opening to many new possibilities in a market that is expected to grow five-fold to $100B by 2030.
H2FIELD-1 marks the start of H3 Dynamics’ foray into hydrogen infrastructure solutions for small, unmanned and increasingly large aircraft, from airfields to airports - with increasingly large output power and hydrogen storage capabilities.
“We are the evolutionary starting point to increasingly large hydrogen powered flight platforms, where testing, certification and regulatory approval challenges vary based on aircraft weight. We want to mature hydrogen technology in today’s existing uncrewed aviation market - and that includes working out hydrogen logistics and refueling systems,” says Taras Wankewycz, CEO and co-Founder at H3 Dynamics.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is on a mission to decarbonize aviation. While the commercial opportunities around passenger-scale hydrogen aviation propulsion will take many more years to mature, the company is following a “start small” product and services roadmap that solves safety, technical, regulatory challenges by adding scale, weight and complexity over time. The company employs 94 team members from its 3 regional headquarters in Toulouse, Austin and Singapore. H3 Dynamics is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005066/en/
Contact information
Taras Wankewycz
CEO, H3 Dynamics
taras@h3dynamics.com
www.h3dynamics.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom